Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03748953 |
| Consolidated Lead Sponsor | Takeda |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 37 participants (ACTUAL) |
| Registered Start Date | 2019-01-24 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Peking University Third Hospital | Beijing, China | Open Hospital Dossier -> |
| Peking Union Medical College Hospital | Beijing, China | Open Hospital Dossier -> |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, China | Open Hospital Dossier -> |
| Shengjing hospital of China medical university | Shenyang, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.